Skip to content
Screener

Ardelyx ARDX Financing Cash Flow

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$1.48B+44.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$122K+101%
AbbVie logo
AbbVieABBV
$919M+173%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from Loan Agreement, net of costs81,87148,668
Repayment of Loan Agreement, including fees(33,831)
Proceeds from issuance of common stock under equity incentive plans7,1222,470
Net cash provided by financing activities55,16251,138
Net increase in cash and cash equivalents29,19225,113
Cash and cash equivalents at beginning of period67,99964,932
Cash and cash equivalents at end of period$97,191$90,045
Supplemental disclosure of cash flow information

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's financing cash flow?
Ardelyx (ARDX) reported financing cash flow of $49.72M in Q2 2026.
How has Ardelyx's financing cash flow changed year-over-year?
Ardelyx's financing cash flow increased by 0.1% year-over-year, from $49.66M to $49.72M.
What is the long-term trend for Ardelyx's financing cash flow?
Over 4 years (2021 to 2025), Ardelyx's financing cash flow has grown at a -10.0% compound annual growth rate (CAGR), from $83M to $54.51M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Ardelyx's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude